The latest research on Myriad Genetics trims the modeled fair value only slightly, from US$8.32 to US$8.12 per share, and aligns a new US$7 price target with expectations across the broader ...
Merck (NYSE:MRK) received Health Canada approval for ENFLONSIA, its RSV preventive therapy for infants. The authorization expands Merck's presence in the respiratory and infectious disease space in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results